Inmune Bio, Inc. Files Amendment No. 1 to Annual Report on Form 10-K

TL;DR

<b>Inmune Bio, Inc. has filed an amendment to its 2023 10-K report, providing updated information.</b>

AI Summary

Inmune Bio, Inc. (INMB) filed a Amended Annual Report (10-K/A) with the SEC on April 16, 2024. Inmune Bio, Inc. filed an amendment (No. 1) to its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing was submitted on April 16, 2024. The company's principal executive offices are located at 225 NE Mizner Blvd, Suite 640, Boca Raton, FL 33432. Inmune Bio, Inc. is incorporated in Nevada and its IRS Employer Identification No. is 47-5205835. The company's common stock is traded on The Nasdaq Stock Market LLC under the symbol INMB.

Why It Matters

For investors and stakeholders tracking Inmune Bio, Inc., this filing contains several important signals. This amendment indicates that the company is providing updated or corrected information for its fiscal year 2023, which could affect investor understanding of its financial position and operations. As a smaller reporting company and an emerging growth company, these filings are crucial for investors to track the company's progress and compliance with reporting requirements.

Risk Assessment

Risk Level: low — Inmune Bio, Inc. shows low risk based on this filing. The filing is an amendment to a previous report, suggesting it's for clarification or correction rather than a new material event, thus posing low immediate risk.

Analyst Insight

Review the specific changes made in Amendment No. 1 to the 10-K filing to understand any updated financial or operational details.

Key Numbers

• 20231231 — Fiscal Year End (Reported fiscal year end)
• 20240416 — Filing Date (Date of filing)
• 001-38793 — Commission File Number (SEC file number)

Key Players & Entities

• Inmune Bio, Inc. (company) — Filer name
• 2024-04-16 (date) — Filing date
• December 31, 2023 (date) — Fiscal year end
• 225 NE Mizner Blvd, Suite 640, Boca Raton, FL 33432 (address) — Business address
• Nevada (jurisdiction) — State of incorporation
• 47-5205835 (identifier) — IRS Number
• INMB (ticker) — Trading Symbol
• The Nasdaq Stock Market LLC (company) — Market where traded

FAQ

Risk Factors

• Reporting Requirements [medium — regulatory]: The company must comply with Section 13 or 15(d) of the Securities Exchange Act of 1934, including filing all required reports.

Industry Context

Inmune Bio, Inc. operates in the biological products sector, focusing on the development of therapeutics.

Regulatory Implications

The company is subject to the reporting and filing requirements of the Securities Exchange Act of 1934, as indicated by its Form 10-K/A filing.

What Investors Should Do

1. Review the specific amendments made in this 10-K/A filing.
2. Monitor future SEC filings for updates on Inmune Bio's financial performance and strategic developments.
3. Assess the company's classification as a smaller reporting company and emerging growth company in relation to its disclosure obligations.

Key Dates

• 2023-12-31: Fiscal Year End — The period covered by the annual report.
• 2024-04-16: Filing Date — Date of submission for the 10-K/A amendment.

Year-Over-Year Comparison

This filing is an amendment to the previously filed 10-K for the fiscal year ended December 31, 2023, indicating updates or corrections to the original report.

Key Financial Figures

• $0.001 — e of Market Where Traded Common Stock ($0.001 par value) INMB The Nasdaq Stock Market
• $5.3 b — ing to transactions valued in excess of $5.3 billion, and has significant experience i
• $930 million — f executive teams that have raised over $930 million in private and public financing, and th

Filing Documents

• ea0203836-10ka1_inmune.htm (10-K/A) — 255KB
• ea020383601ex31-3_inmune.htm (EX-31.3) — 4KB
• ea020383601ex31-4_inmune.htm (EX-31.4) — 4KB
• 0001213900-24-033418.txt (&nbsp;) — 527KB
• inmb-20231231.xsd (EX-101.SCH) — 3KB
• inmb-20231231_def.xml (EX-101.DEF) — 17KB
• inmb-20231231_lab.xml (EX-101.LAB) — 36KB
• inmb-20231231_pre.xml (EX-101.PRE) — 18KB
• ea0203836-10ka1_inmune_htm.xml (XML) — 8KB

Executive Compensation

Executive Compensation 8 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 11 Item 13. Certain Relationships and Related Transactions, and Director Independence 12 Item 14. Principal Accountant Fees and Services 13 PART IV Item 15. Exhibits and Financial Statement Schedules 14

Signatures

Signatures 15 i PART III

Directors, Executive Officers and

Item 10. Directors, Executive Officers and Corporate Governance. Information About Our Directors and Executive Officers Set forth below are the Company's Directors and Executive Officers as of December 31, 2023, together with an overview of their professional experience and expertise. Name Positions and Offices Held with INmune Bio Director Since Age Raymond J. Tesi, MD President and CEO, Director 2015 68 David J. Moss Chief Financial Officer, Treasurer and Secretary N/A 53 Mark Lowdell, PhD Chief Scientific Officer N/A 61 J. Kelly Ganjei Director 2016 50 Tim Schroeder Director 2016 66 Scott Juda, J.D. Director 2018 53 Edgardo Baracchini, PhD Director 2019 64 Marcia Allen Director 2019 73 The names and certain biographical information about our current directors, including each director's business experience, director position held, information regarding involvement in certain legal or administrative proceeding, if applicable, and the director's experiences, qualifications, attributes, or skills are set forth below. Raymond J. Tesi, M.D. has been the Company's President, Chief Executive Officer and a member of the board of directors of the Company since the formation of the Company in September 2015. Dr. Tesi is currently a board member for Bexion Pharmaceuticals. From November 2011 until May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development stage biotech formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was founder, CEO and President of Coronado Biosciences. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi was formerly a licensed p

View Full Filing

View this 10-K/A filing on SEC EDGAR